Immunological and Virological Responses to Highly Active Antiretroviral Therapy in HIV-1 Infected Children. 2017

Ravinder Singh, and Aparna Mukherjee, and Mohit Singla, and Bimal Kumar Das, and Sushil Kumar Kabra, and Rakesh Lodha
Department of Pediatrics, All India Institute of Medical Sciences, Room no. 3061A, New Delhi, 110029, India.

OBJECTIVE To evaluate immunological and virological outcomes in human immunodeficiency virus (HIV) infected children at six months of highly active antiretroviral therapy (HAART). METHODS Records of HIV infected children <15-y-old were reviewed to identify those who were initiated highly active antiretroviral therapy between 2010 and 2014 and had CD4+ T cell percentage and HIV-1 viral load report at baseline visit and after 6 mo of initiation of the treatment. RESULTS Seventy-four HIV infected children [26% girls, median age IQR 36 (24-108) mo] were included in the study. At the end of six months of HAART, median increase of 11% (6-15%) in CD4+ T cell percentage from the baseline levels was observed; nineteen (26%) children showed an increase in CD4+ T cell percentage of 15% or more at 6 mo. Viral load was undetectable (<47 copies/ml) in 27 (36.4%) children; 21 (28.3%) children had 47- < 500 copies/ml; 16 (21.6%) children had 500- < 10,000 copies/ml and 10 (13.5%) children had ≥10,000 copies/ml. At six months, only 15 (20.2%) children exhibited positive immuno-virological response to HAART (≥ 15% increase in CD4% and <47 HIV-1 RNA copies/ml). CONCLUSIONS While HAART was effective in improving the immunological and virological parameters in the index cohort of children, virological responses were less robust.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D018791 CD4 Lymphocyte Count The number of CD4-POSITIVE T-LYMPHOCYTES per unit volume of BLOOD. Determination requires the use of a fluorescence-activated flow cytometer. Lymphocyte Count, CD4,T4 Lymphocyte Count,CD4 Cell Counts,CD4 Counts,CD4+ Cell Counts,CD4+ Counts,CD4 Cell Count,CD4 Count,CD4 Lymphocyte Counts,CD4+ Cell Count,CD4+ Count,Count, T4 Lymphocyte,Counts, T4 Lymphocyte,Lymphocyte Count, T4,Lymphocyte Counts, CD4,Lymphocyte Counts, T4,T4 Lymphocyte Counts

Related Publications

Ravinder Singh, and Aparna Mukherjee, and Mohit Singla, and Bimal Kumar Das, and Sushil Kumar Kabra, and Rakesh Lodha
March 2000, Acta paediatrica (Oslo, Norway : 1992),
Ravinder Singh, and Aparna Mukherjee, and Mohit Singla, and Bimal Kumar Das, and Sushil Kumar Kabra, and Rakesh Lodha
August 2020, Environmental health and preventive medicine,
Ravinder Singh, and Aparna Mukherjee, and Mohit Singla, and Bimal Kumar Das, and Sushil Kumar Kabra, and Rakesh Lodha
September 2000, AIDS (London, England),
Ravinder Singh, and Aparna Mukherjee, and Mohit Singla, and Bimal Kumar Das, and Sushil Kumar Kabra, and Rakesh Lodha
September 2006, The Journal of infectious diseases,
Ravinder Singh, and Aparna Mukherjee, and Mohit Singla, and Bimal Kumar Das, and Sushil Kumar Kabra, and Rakesh Lodha
February 2002, The Lancet. Infectious diseases,
Ravinder Singh, and Aparna Mukherjee, and Mohit Singla, and Bimal Kumar Das, and Sushil Kumar Kabra, and Rakesh Lodha
November 2006, AIDS (London, England),
Ravinder Singh, and Aparna Mukherjee, and Mohit Singla, and Bimal Kumar Das, and Sushil Kumar Kabra, and Rakesh Lodha
April 2004, The new microbiologica,
Ravinder Singh, and Aparna Mukherjee, and Mohit Singla, and Bimal Kumar Das, and Sushil Kumar Kabra, and Rakesh Lodha
July 2007, Journal of acquired immune deficiency syndromes (1999),
Ravinder Singh, and Aparna Mukherjee, and Mohit Singla, and Bimal Kumar Das, and Sushil Kumar Kabra, and Rakesh Lodha
May 2002, Clinical and experimental immunology,
Ravinder Singh, and Aparna Mukherjee, and Mohit Singla, and Bimal Kumar Das, and Sushil Kumar Kabra, and Rakesh Lodha
October 2013, Journal of viral hepatitis,
Copied contents to your clipboard!